Apontis Pharma: A classic growth share - what you should know

Die Demografie ist eine wichtige Wissenschaft. Sie untersucht, wie sich die Struktur einer Bevölkerung entwickelt. Fest steht, dass der Anteil der über 65-Jährigen an der Gesamtbevölkerung zunehmen wird. Von Jörg Lang

Ensures that the baby booming generation gets older and life expectancy increases.Medicines are often necessary over the years.Numerous older patients take a cocktail every day from different drugs. Der Börsennewcomer Apontis Pharma ist angetreten, um die Einnahmetreue zu verbessern und so den Therapieerfolg zu erhöhen.

Apontis is not a blank leaf.The roots go back to black pharmaceuticals, which more experienced investors can still remember.The company was taken over in 2006 by UCB, based in Belgium. Der Bereich innere Medizin passte aber nicht ins Konzept, wurde später ausgegliedert und an die Beteiligungsfirma Paragon verkauft.In 2021 the IPO took place.Apontis has had experience for cardiovascular diseases for decades and also has good sales representations for 23,000 doctors.

Apontis Pharma: Eine klassische Growth-Aktie - Was Sie wissen sollten

A pill instead of three or four

When treating high blood pressure, the doctor often has to use several active ingredients.Apontis gets on here.After the patient has been stopped.That has decisive advantages.Studies show that the fidelity of income increases with only one pill and thus the success of therapy;The risk of negative events such as strokes drops.That is the basis of the stock market story.Apontis has 30.June already 235,000 patients who use one of the nine different single-pool therapies.The growth rates are high.The sale rose by over 80 percent within one year, the area made up more than half of the total proceeds in the first half of the year.Apontis is already operational, measured by the operating result, with a margin of 11.8 percent quite profitable.At the same time, the growth opportunities are immense.

There are more than 20 million patients in Germany alone who suffer and can be achieved with high blood pressure and fat metabolism disorders.Due to demographic change, there will be more every day.The development of new active ingredients ensures potential.Of course, there is a lot included in the stock market value of 204 million euros.However, if the company maintains the course chosen with the appropriate profitability, the stock will hardly disconnect from it.

The stock is a classic growth value that is suitable for the high rating for risk -siders and long -term investors.Orders must be limited.Please also note the stop course.Recommendation: Buy